Clinical efficacy of atorvastatin and lipo-prostaglandin E1 combined with hyperbaric oxygen on 102 cases of diabetic lower extremity vascular disease
10.3760/cma.j.cn311847-20200629-00269
- VernacularTitle:阿托伐他汀和前列地尔脂微球载体联合高压氧治疗糖尿病下肢血管病变102例疗效观察
- Author:
Wenbo LI
1
;
Chunpeng DIAO
;
Yang YU
;
Xingbo LYU
;
Lefeng QU
Author Information
1. 265700 山东省烟台，龙口市人民医院血管外科
- Publication Type:Journal Article
- Keywords:
Atorvastatin;
LipoPGE1;
Hyperbaric oxygen;
Diabetes;
Lower extremity vascular disease
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2020;27(5):547-552
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and mechanism of atorvastatin and Lipo-prostaglandin E1 (LipoPGE1) combined with hyperbaric oxygen (HBO) in the treatment of diabetic lower extremity vascular disease.Methods:A total of 194 patients with diabetic lower extremity ischemic disease received conservative treatment at the Department of Vascular Surgery of Longkou People’s Hospital from October 2016 to October 2019 were included into a retrospective analysis, who were divided into observation group ( n=102) and control group ( n=92) according to the treatment. The control group was treated with atorvastatin and LipoPGE1 on the basis of conventional symptomatic treatment, while the observation group was treated with HBO on the basis of that of the control group. The peak systolic velocity (Vmax), resistance index (RI), and ankle brachial index (ABI) of popliteal artery, anterior and posterior tibial artery, and dorsalis pedis artery were measured before and after treatment by color Doppler ultrasound. The skin temperature and transcutaneous oxygen partial pressure (TcPO 2) were recorded before and after treatment. The levels of inflammatory factor interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in serum were detected by enzyme-linked immunosorbent assay (ELISA) and that of C-reactive protein (CRP) was detected by fluorescence method. The whole blood high, low, and medium shear rate, plasma viscosity, and fibrinogen (Fib) of the two groups were detected by digital noninvasive hemodynamic detector. Results:After 3 courses of treatment, the skin temperature, TcPO 2, and ABI of the two groups were significantly higher than those before treatment, and the skin temperature, TcPO 2, and ABI of the observation group were significantly higher than those of the control group ( P<0.05). The limb pain score and intermittent claudication score of the two groups were significantly lower than those before treatment; and after treatment, the limb pain score and intermittent claudication score of the observation group were significantly lower than those of the control group ( P < 0.05). The Vmax of popliteal artery, anterior and posterior tibial artery, and dorsalis pedis artery of the two groups were significantly higher than those before treatment, and the RI was significantly lower than that before treatment; and after treatment, the Vmax of popliteal artery, anterior and posterior tibial artery, and dorsalis pedis artery of the observation group were significantly higher than those of the control group, and the RI was significantly lower than that of the control group ( P<0.05). The levels of serum TNF- α, IL-6, and CRP of the two groups were significantly lower than those before treatment; and after treatment, the levels of TNF-α, IL-6, and CRP of the observation group were significantly lower than those of the control group ( P < 0.05). The whole blood high, low, and medium shear rate, plasma viscosity, and Fib of the two groups were significantly lower than those before treatment; and after treatment, those of the observation group were significantly lower than those of the control group, the differences were statistically significant ( P< 0.05). Conclusion:Atorvastatin and LipoPGE1 combined with HBO can significantly improve the clinical symptoms of the patients with diabetic lower extremity vascular disease and restore the damaged neurovascular function, which is mainly achieved by reducing the inflammatory factors and improving the level of hemorheology of the patients with diabetic lower extremity vascular disease.
